Vanda Q2 net loss widens to $27.2M; Fanapt sales up 27% to $29.3M

Vanda Pharmaceuticals Inc.

2025-Q2 EPS reported -$0.96 revenue$102,631,000

Fanapt net product sales $29.3M (+27% YoY); HETLIOZ $16.2M (-13%), PONVORY $7.1M (-18%).
Net loss $27.2M (diluted EPS -$0.46) vs. net loss $4.5M (-$0.08) in Q2 2024.
Cash $325.6M, down $15.4M from Q1 2025; full-year revenue guidance reaffirmed $210-250M.
Regulatory milestones: Bysanti NDA PDUFA Feb 21, 2026; Tradipitant NDA PDUFA Dec 30, 2025; Imsidolimab BLA submission expected 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.